Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab + HuMax-IL8 in Head & Neck Cancer
NCT04848116Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2021
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adakitug in head and neck squamous cell carcinoma (HNSCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Apr 2021; status: active, not recruiting.
02
Drugs
adakitug
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04848116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848116.